Mitsubishi UFJ Asset Management Co. Ltd. Purchases New Stake in CVS Health Corporation $CVS

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,118,927 shares of the pharmacy operator’s stock, valued at approximately $322,653,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. bought a new stake in shares of CVS Health in the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new position in CVS Health in the fourth quarter valued at approximately $28,000. Global Trust Asset Management LLC grew its holdings in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. bought a new position in CVS Health during the fourth quarter valued at $28,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other CVS Health news, Director Larry Robbins sold 1,018,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00. Following the transaction, the director directly owned 5,195,261 shares in the company, valued at $487,419,387.02. This represents a 16.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is owned by corporate insiders.

CVS Health Stock Performance

NYSE CVS opened at $93.99 on Tuesday. The company’s 50 day simple moving average is $102.46 and its two-hundred day simple moving average is $88.41. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1 year low of $69.40 and a 1 year high of $110.68. The stock has a market capitalization of $120.21 billion, a PE ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s payout ratio is presently 70.37%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CVS. HSBC restated a “hold” rating and issued a $103.00 target price on shares of CVS Health in a research note on Monday, July 6th. Truist Financial lifted their price objective on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Robert W. Baird set a $107.00 price objective on CVS Health in a research note on Thursday, August 6th. DA Davidson upped their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Sanford C. Bernstein increased their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.